Please login to the form below

Not currently logged in
Email:
Password:

GSK completes acquisition of Steifel

GSK has acquired the total share capital of Steifel Laboratories Inc in a cash deal worth $2.9bn

GlaxoSmithKline (GSK) has acquired the total share capital of Steifel Laboratories Inc in a cash deal worth $2.9bn.

As part of the deal, GSK has assumed $400m of net debt and may, dependent on the future performance of the business, be obliged to make additional cash payments of up to $300m.

GSK will operate its new dermatology business unit under the name Steifel, a GSK company.

Charles Stiefel, chairman of Stiefel, said: "As part of GSK, we are stronger, more competitive and continue to be a driving force in dermatology around the world. We are excited to combine GSK's prescription dermatology products, such as Bactroban, Cutivate and Altabax, with Stiefel's portfolio, including brands such as Duac, Olux E and Soriatane."

In 2008, Steifel products made approximately $900m in sales. This, combined with GSK's 2008 prescription dermatology product sales of $550m, creates pro forma revenues of around $1.5m – an 8 per cent share of the global prescription dermatology market.

22nd July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics